logo
Plus   Neg
Share
Email

Astellas Pharma Gets Positive CHMP Opinion For XOSPATA

Astellas Pharma Inc. said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA has adopted a positive opinion recommending the oral once-daily therapy XOSPATA or gilteritinib as a monotherapy for the treatment of adult patients who have relapsed or refractory (resistant to treatment) acute myeloid leukemia or AML with a FLT3 mutation (FLT3mut+).

If approved by the European Commission, gilteritinib has the potential to improve treatment outcomes for AML patients with the most common mutations - FLT3 internal tandem duplication (ITD) and FLT3 tyrosine kinase domain (TKD) - and would be one of the few advances for the treatment of AML in Europe over the past 40 years.

Gilteritinib received accelerated assessment from the EMA, which allowed the CHMP to reduce the timeframe for approval.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS has issued a public health alert for certain beef meatball products by Whole Foods Market, Inc. due to misbranding and undeclared milk, a known allergen. As per the warning, Amazon's Whole Foods Market sold an undetermined amount of beef meatballs with marinara sauce that were misbranded. Dr. Reddy's Laboratories, Inc. is recalling about 21,400 blister packages of certain prescription medications citing the risk of poisoning to children, the U.S. Consumer Product Safety Commission said. The recall involves various medications, such as Imatinib Mesylate Tablets 100 mg and 400 mg; Pregabalin Capsules 50 mg, 75 mg, 100 mg, and 150 mg; Sevelamer Carbonate Tablets 800 mg.... The Australian government has passed the newly amended Media Bargaining Code in the parliament which requires technology giants Facebook and Google to pay for local Australian news content that is shared on their platforms.
Follow RTT